Thrombosis in atherogenesis.
This review addresses the question of the involvement of fibrin in the development of atherosclerotic plaques. Numerous studies in the older literature demonstrated the presence of fibrinogen and/or fibrin in plaques, but the techniques that were available (mainly immunochemistry and immunohistochemistry with polyclonal antifibrinogen antibodies) did not clearly distinguish fibrinogen from fibrin or fibrinogen/fibrin degradation products. Some of these studies suggested that the fibrinogen-related protein within lesions resulted from incorporation of thrombi into lesions, while other studies suggested that fibrinogen itself entered the vessel wall. Newer studies by the authors and collaborators used specific antibodies for various fibrinopeptides to quantitate fibrinogen, fibrin I, fibrin II, and fragment X in thrombi and different histologic types of plaques. These studies showed that normal aortas contained fibrinogen and that fatty and fibrous plaques contained fibrinogen, fibrin I, and fibrin II, while complicated plaques contained fibrin II and fragment X, indicating a progression from fibrinogen to fibrin and fibrinogen/fibrin degradation products in parallel with increasing severity of the lesions. Later studies by the authors and collaborators used a sensitive immunohistochemical technique with monoclonal antibodies to demonstrate the distribution of fibrinogen-related antigens. Patterns suggesting incorporation of thrombi were seen, as were patterns suggesting formation of fibrin in association with arterial wall monocyte/macrophages and smooth muscle cells. The data from these various studies suggest the possibility that fibrin formation occurs within the arterial wall and contributes to plaque formation.
Kaplan
K L
KL
Department of Medicine, Columbia-Presbyterian Medical Center, New York, New York.
Bini
A
A
D000941:Antigens / Q000032:analysis; D001161:Arteriosclerosis / Q000209:etiology* / Q000473:pathology; D004730:Endothelium, Vascular / Q000378:metabolism / Q000502:physiology; D005337:Fibrin / Q000032:analysis / Q000502:physiology; D005338:Fibrin Fibrinogen Degradation Products / Q000032:analysis; D005340:Fibrinogen / Q000032:analysis; D006801:Humans; D007120:Immunochemistry; D007150:Immunohistochemistry; D013927:Thrombosis / Q000150:complications*
D000941:Antigens; D005338:Fibrin Fibrinogen Degradation Products; C023456:fibrinogen-related antigen; D005337:Fibrin; D005340:Fibrinogen